Royal Philips reported a strong Q3 2025, driven by an 8% growth in order intake and robust performance across all business segments, particularly Personal Health. The company's adjusted EBITDA margin expanded despite ongoing tariff impacts, reflecting effective cost management and innovation.
- Order intake increased by 8%, marking the fourth consecutive quarter of growth, with strong momentum in North America.
- Comparable sales growth improved to 3% year-on-year, supported by solid demand in Personal Health and Connected Care.
- Adjusted EBITDA margin rose by 50 basis points to 12.3%, showcasing the effectiveness of productivity initiatives.
- The company reiterated its full-year comparable sales growth outlook of 1% to 3%, with a projected adjusted EBITDA margin expected at the upper end of the 11.3% to 11.8% range.
- Free cash flow guidance remains stable at between EUR 0.2 billion and EUR 0.4 billion for the full year.
Community Discussion